 
 
 
July 15, 2024 
 
To, 
Listing/ Compliance Department  
BSE LTD.  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001  
 
SCRIP CODE: 543748 
 
Dear Sir/Madam,  
 
To, 
Listing/ Compliance Department 
National Stock Exchange of  
India Limited  
“Exchange Plaza”, Plot No. C/1, 
G Block, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
SYMBOL: AARTIPHARM 
 
 
 
Sub: Business Responsibility and Sustainability Report for 
the Financial Year 2023-24 
Ref:  Regulation 34(2)(f) of SEBI (Listing Obligations and 
Disclosure Requirements) Regulations, 2015 (“Listing 
Regulations”).  
 
In continuation to our intimation dated July 15, 2024 regarding the Annual Report for the 
Financial Year 2023-24, along with Notice of the 5th Annual General Meeting, and pursuant to 
Regulation 34(2)(f) of the Listing Regulations, we are submitting herewith the Business 
Responsibility and Sustainability Report for the Financial Year 2023-24. 
 
Please take the same on your records. 
 
Thanking you,  
 
Yours faithfully, 
For AARTI PHARMALABS LIMITED 
 
 
 
 
NIKHIL NATU 
COMPANY SECRETARY 
ICSI M. NO. A27738 
 
Encl.: a/a 
 
NIKHIL 
PANDURANG 
NATU
Digitally signed by 
NIKHIL PANDURANG 
NATU 
Date: 2024.07.15 
19:34:57 +05'30'
Business Responsibility and Sustainability  
Reporting
SECTION A: GENERAL DISCLOSURES
I. 	
Details of the Listed Entity
Sr. 
No 
Particulars 
1.
Corporate Identity Number (CIN) of the Company
L24100GJ2019PLC110964
2.
Name of the Company
Aarti Pharmalabs Limited
3.
Year of Incorporation
22.11.2019
4.
Registered office address
Plot No 22/C/1 & 22/C/2, 1st Phase, GIDC Vapi 396195, 
Valsad, Gujarat
5.
Corporate office address
204, Udyog Kshetra, 2nd floor, Mulund Goregaon Link Road, 
Mulund West, Mumbai-400080 Maharashtra
6.
E-mail id
info@aartipharmalabs.com
7.
Telephone
+91 022-69436100
8.
Website
www.aartipharmalabs.com
9.
Financial year for which reporting is being done
April 1, 2023, to March 31, 2024
10. Name of the Stock Exchange(s) where shares are listed
a.	
BSE Limited
b.	
National Stock Exchange of India Limited
11. Paid-up capital
` 45,31,30,040.00
12. Name and contact details of the person who may be 
contacted in case of any queries on the BRSR report
Smt. Hetal Gogri Gala
Vice Chairperson & Managing Director
Tel: +91 022-69436100
Email: infoapi@aartipharmalabs.com 
13. Reporting boundary
Standalone basis
14. Name of assurance provider
Not Applicable, as BRSR Core Assurance is not mandatory 
for the Company.
15. Type of assurance obtained
II. 	
Products/services
16.	 Details of business activities
Sr. 
No.
Description of main 
activity
Description of business activity
% of total turnover 
contributed
1
Manufacturing of 
Pharmaceuticals and 
Nutraceuticals
Development of Active Pharmaceutical Ingredients (API) and New 
Chemical Entities (NCE), API intermediates, Regulatory Starting 
Materials (RSM), Basic Starting Materials, Key Building Blocks, 
and Xanthine Derivatives for use in clinical testing and commercial 
production.
99.7%
17.	 Products/services sold by the entity
S. 
No.
Product/Service
NIC Code
% of total Turnover 
contributed
1
API (Active Pharmaceutical Ingredients), Pharmaceutical Intermediates, 
New Chemical Entities
210
79.56%
2
Xanthine Derivatives
1104
20.14%
Annual Report 2023-24
Corporate Overview
Statutory Reports
Financial Statements
87
1-31
32-115
116-256
III. 	 OPERATIONS 
18.	 Number of locations where plants and/or operations/offices of the entity are situated.
Location
Number of plants*
Number of offices
Total
National
14*
3
17
International
0
0
0
	
*3 R&D units of the company is included under Number of plants.
19.	 Markets served by the entity
	
a.	
Number of locations – This refers to locations where goods were transported to during the financial year, however 
the consumption of final product & even customer footprint is larger.
Locations
Number
National (No. of states)
20
International (No. of countries)
64
	
b.	
What is the contribution of exports as a percentage of the total turnover of the entity?
	
	
The company has a global presence with exports accounting for approximately 51% of its revenue.
	
c.	
A brief on types of customers
	
	
Aarti Pharmalabs Limited is a leader in the B2B sector, providing a wide range of services to diverse industries. 
Our extensive client base includes sectors such as pharmaceuticals, food and beverages, polymers and additives, 
agrochemicals, intermediates for innovators, dyes, and pigments. We cater to both national and international markets, 
tailoring our offerings to meet the unique needs and demands of our clients.
IV. 	 EMPLOYEES
20.	 Details as of March 31, 2024
	
a.	
Employees and workers (including differently abled)
S. 
No.
Particulars
Total (A)
Male
Female
No. (B)
% (B / A)
No. (C)
% (C / A)
EMPLOYEES
1
Permanent (D)
1,627
1,543
94.83%
84
5.17%
2
Other than permanent (E)
87
67
77.01%
20
22.99%
3
Total employees (D + E)
1,714
1,610
93.93%
104
6.07%
WORKERS
4
Permanent (F)
468
468
100.0%
0
0.0%
5
Other than permanent (G)
1,001
994
99.30%
7
0.70%
6
Total workers (F + G)
1,469
1,462
99.93%
7
0.07%
	
b.	
Differently abled employees
S. 
No.
Particulars
Total (A)
Male
Female
No. (B)
% (B / A)
No. (C)
% (C / A)
DIFFERENTLY ABLED EMPLOYEES
1
Permanent (D)
2
2
100%
0
0%
2
Other than permanent (E)
0
0
0%
0
0%
3
Total differently abled employees (D + E)
2
2
100%
0
0%
DIFFERENTLY ABLED WORKERS
4
Permanent (F)
1
1
100%
0
0%
5
Other than permanent (G)
0
0
0%
0
0%
6
Total differently abled workers (F + G)
1
1
100%
0
0%
Aarti Pharmalabs Limited
88
21.	 Participation/inclusion/representation of women
Total (A)
No. and percentage of Females
No. (B)
% (B / A)
Board of Directors
10*
3
33.33%
Key Management Personnel (other than BoD)
2
0
0%
	
* The Board of Directors consist of 2 Managing Directors and 8 Non-Executive Directors. Besides, the Company Secretary and Chief Financial 
Officer have been considered for the purpose of Key Management Personnel (under Section 203 of the CA 2013). Besides, the Executive 
Directors have not been considered again under the Key Managerial Personnel, since they have been separately disclosed under the Board 
of Directors.
22.	 Turnover rate for permanent employees
FY 2023-24 (%)
FY 2022-23 (%)
FY 2021-22 (%)
Male
Female
Total
Male
Female
Total
Male
Female
Total
Permanent Employees
9.17
8.25
9.02
11.67
15.27
11.85
12.82
22.58
13.27
Permanent Workers
4.77
0
4.77
8.09
0
8.09
9.33
0
9.33
V. 	 HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES (INCLUDING JOINT VENTURES)
23.	 (a) 	 Names of holding / subsidiary / associate companies / joint ventures
S. 
No.
Name of the holding/
subsidiary/ associate 
companies/joint  
ventures (A)
Indicate whether 
holding/ Subsidiary/ 
Associate/ Joint 
Venture
% of shares 
held by listed 
entity
Does the entity indicated at column 
A, participate in the Business 
Responsibility initiatives of the 
listed entity? (Yes/No)
1
Ganesh Polychem Limited
Jointly Controlled
50%
No
2
Aarti USA Inc.
Subsidiary
100%
No
3
Aarti Pharmachem Limited
Subsidiary
100%
No
VI. 	 CSR DETAILS
24.	 (i)	
Whether CSR is applicable as per section 135 of Companies Act, 2013: Yes
	
(ii)	 Turnover	 	
	
	
: ` 15,02,13,19,770.00
	
(iii)	 Net worth	
	
	
: ` 16,21,45,97,787.00
VII. 	TRANSPARENCY AND DISCLOSURES COMPLIANCES
25.	 Complaints/grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business 
Conduct (NGRBC)
	
The Company’s key stakeholders include investors, customers, employees, value chain partners/ suppliers and community 
besides governments/regulatory authorities.
Stakeholder 
group from 
whom 
complaint is 
received
Grievance Redressal 
Mechanisms in Place 
(Yes/No)
FY 2023-24
FY 2022-23
(If yes, then provide 
web-link for 
grievance redress 
policy)
Number of 
complaints 
filed during 
the year
Number of 
complaints 
pending 
resolution at 
close of the year
Remarks
Number of 
complaints 
filed during 
the year
Number of 
complaints 
pending 
resolution at 
close of the year
Remarks
Communities
-
0
0
-
0
0
-
Investors 
(other than 
shareholders)
https://www.
aartipharmalabs.
com/investors-
relations 
0
0
-
0
0
-
Annual Report 2023-24
Corporate Overview
Statutory Reports
Financial Statements
89
1-31
32-115
116-256
Stakeholder 
group from 
whom 
complaint is 
received
Grievance Redressal 
Mechanisms in Place 
(Yes/No)
FY 2023-24
FY 2022-23
(If yes, then provide 
web-link for 
grievance redress 
policy)
Number of 
complaints 
filed during 
the year
Number of 
complaints 
pending 
resolution at 
close of the year
Remarks
Number of 
complaints 
filed during 
the year
Number of 
complaints 
pending 
resolution at 
close of the year
Remarks
Shareholders
https://www.
aartipharmalabs.
com/investors-
relations
0
0
-
0
0
-
Employees and 
workers
https://www.
aartipharmalabs.
com/investors/vigil-
mechanism-policy-
feb-2023.pdf 
0
0
-
0
0
-
Customers
https://www.
aartipharmalabs.
com/contact
17
3
APL shall 
ensure 
timely 
resolution 
of all the 
pending 
complaints
16
3
All 
Complaints 
were resolved 
successfully
Value Chain 
Partners
https://www.
aartipharmalabs.
com/contact 
0
0
-
0
0
-
26.	 Overview of the entity’s material responsible business conduct issues
	
Please indicate material responsible business conduct and sustainability issues pertaining to environmental and social 
matters that present a risk or an opportunity to your business, rationale for identifying the same, approach to adapt or 
mitigate the risk, as per the following format:
	
Material topic identification was conducted through a survey with key stakeholders identified. Board members, Investors/
Analysts, Employees, Customers, Bankers, and Suppliers have participated in the survey. The material topics are suitably 
incorporated in the Environment, Social and Governance (ESG) Strategy of the Company.  
Sr. 
No.
Material issue 
identified
Indicate 
whether risk 
or opportunity
Rationale for identifying the 
risk/opportunity
In case of risk, approach 
to adapt or mitigate
Financial 
implications of the 
risk or opportunity 
1.
Learning and 
Development
Opportunity
Investing in employee learning 
and development ensures a 
skilled and motivated workforce, 
enhancing innovation and 
productivity.
NA
Positive
2.
Material 
Sourcing and 
Efficiency
Risk and 
Opportunity
Efficient sourcing reduces costs 
and environmental impact, 
while poor practices can lead to 
supply chain disruptions.
Implement stringent 
supplier assessments 
and sustainable sourcing 
practices.
Positive
Aarti Pharmalabs Limited
90
Sr. 
No.
Material issue 
identified
Indicate 
whether risk 
or opportunity
Rationale for identifying the 
risk/opportunity
In case of risk, approach 
to adapt or mitigate
Financial 
implications of the 
risk or opportunity 
3.
Supplier 
Environmental 
Assessment
Risk
Ensuring suppliers meet 
environmental standards 
reduces APL’s exposure to 
environmental risks and 
regulatory penalties.
Regular audits and 
collaboration with 
suppliers to improve 
environmental 
performance.
Negative
4.
Supplier Social 
Assessment
Risk
Ensuring suppliers adhere to 
social standards mitigates risks 
related to labor practices and 
human rights violations.
Conduct regular social 
audits and engage in 
supplier development 
programs.
Negative
5.
GHG Emissions Risk
High GHG emissions expose 
APL to regulatory penalties and 
reputational damage.
Implement emission 
reduction strategies 
and invest in cleaner 
technologies.
Negative
6.
Climate 
Change
Risk and 
Opportunity
Climate change poses risks 
to operations but also offers 
opportunities for innovation in 
sustainability.
Develop climate 
resilience strategies and 
reduce carbon footprint.
Positive
7.
Energy 
Management
Risk and 
Opportunity
Efficient energy use reduces 
costs and environmental 
impact, while poor management 
can lead to higher expenses and 
emissions.
Implement energy-
efficient technologies 
and practices.
Positive
8.
Economic 
Performance
Risk and 
Opportunity
Strong economic performance 
ensures business viability, while 
poor performance can threaten 
sustainability.
Implement robust 
financial management 
and strategic planning.
Positive
9.
Employee 
Wellbeing
Opportunity
Promoting employee wellbeing 
enhances productivity, reduces 
absenteeism, and improves job 
satisfaction.
NA
Positive
10.
Waste 
Management
Risk and 
Opportunity
Efficient waste management 
reduces environmental impact 
and compliance risks while 
offering opportunities for 
resource recovery.
Implement 
comprehensive waste 
reduction and recycling 
programs.
Positive
11.
Water 
Management
Risk and 
Opportunity
Effective water management 
ensures resource availability 
and reduces environmental 
impact, while poor management 
can lead to scarcity and 
regulatory issues.
Implement water-
saving technologies and 
practices.
Positive
12.
Business 
Ethics
Risk 
Upholding high ethical 
standards mitigates risks 
related to legal issues and 
reputational damage.
Implement robust ethics 
training and compliance 
programs.
Negative
Annual Report 2023-24
Corporate Overview
Statutory Reports
Financial Statements
91
1-31
32-115
116-256
Sr. 
No.
Material issue 
identified
Indicate 
whether risk 
or opportunity
Rationale for identifying the 
risk/opportunity
In case of risk, approach 
to adapt or mitigate
Financial 
implications of the 
risk or opportunity 
13.
Risk 
Management
Risk and 
Opportunity
Proactive risk management 
mitigates potential operational, 
financial, and reputational risks.
Develop and implement 
comprehensive 
risk management 
frameworks.
Positive
14.
Data Privacy 
and Security
Risk 
Ensuring data privacy and 
security protects against 
breaches, legal penalties, and 
reputational damage.
Implement robust 
cybersecurity measures 
and data protection 
policies.
Negative
15.
Indirect 
Economic 
Impacts
Risk and 
Opportunity
Understanding and managing 
indirect economic impacts 
can mitigate risks and create 
opportunities for community 
development and business 
growth.
Engage with stakeholders 
to identify and manage 
indirect impacts.
Positive
16.
Marketing and 
Labeling
Risk
Accurate marketing and labeling 
ensure regulatory compliance 
and build consumer trust, 
while inaccuracies can lead to 
legal issues and reputational 
damage.
Implement stringent 
quality control and 
compliance checks.
Negative
17.
Product 
Quality and 
Safety
Risk
Ensuring product quality and 
safety protects consumer 
health, complies with 
regulations, and maintains APL's 
reputation.
Implement rigorous 
quality control and safety 
testing procedures.
Negative
18.
Compliance
Risk
Compliance with laws and 
regulations prevents legal 
penalties and maintains 
operational integrity.
Implement 
comprehensive 
compliance programs 
and regular audits.
Negative
19.
Air Quality
Risk
Maintaining good air quality 
reduces health risks and 
ensures regulatory compliance.
Implement emission 
controls and regular 
monitoring.
Negative
20.
Diversity 
and Equal 
Opportunity
Opportunity
Promoting diversity and equal 
opportunity fosters innovation, 
improves employee morale, and 
enhances reputation.
NA
Positive
21.
Occupational 
Health and 
Safety
Risk 
Ensuring occupational health 
and safety prevents workplace 
accidents, reduces absenteeism, 
and complies with regulations.
Implement robust health 
and safety programs and 
training.
Negative
22.
Customer 
Health and 
Safety
Risk 
Prioritizing customer health and 
safety maintains trust, complies 
with regulations, and protects 
against legal issues.
Implement strict quality 
control and safety 
measures.
Negative
Aarti Pharmalabs Limited
92
Sr. 
No.
Material issue 
identified
Indicate 
whether risk 
or opportunity
Rationale for identifying the 
risk/opportunity
In case of risk, approach 
to adapt or mitigate
Financial 
implications of the 
risk or opportunity 
23.
Local 
Communities 
(CSR)
Opportunity
Engaging with local 
communities through CSR 
initiatives fosters goodwill, 
enhances reputation, and 
contributes to sustainable 
development.
NA
Positive
24.
Non-
discrimination
Opportunity
Upholding non-discrimination 
policies ensures a fair and 
inclusive workplace, enhancing 
employee satisfaction and 
reputation.
NA
Positive
25.
Human Rights
Risk 
Ensuring respect for human 
rights in operations and supply 
chains mitigates risks related 
to legal issues and reputational 
damage.
Implement and enforce 
human rights policies 
and supplier codes of 
conduct.
Negative
26.
Access to 
Healthcare
Opportunity
APL can contribute to improved 
public health by ensuring 
access to affordable and 
effective pharmaceutical 
products.
NA
Positive
Annual Report 2023-24
Corporate Overview
Statutory Reports
Financial Statements
93
1-31
32-115
116-256
SECTION B: MANAGEMENT AND PROCESS DISCLOSURES
Disclosure Questions
P1
P2
P3
P4
P5
P6
P7
P8
P9
POLICY AND MANAGEMENT PROCESS
1.	 a.	 Whether your entity’s policy/policies cover each 
principle and its core elements of the NGRBCs. (Yes/
No)
Y
Y
Y
Y
Y
Y
N
Y
Y
	
b.	  Has the policy been approved by the Board? (Yes/No) The statutory policies are approved by the Board or Board 
Committees, as applicable. Other applicable policies are either 
approved by the Board or by the appropriate authority.
	
c.	 Web Link of the Policies, if available.
P1:
• 
Code of Ethical Conduct: https://www.aartipharmalabs.
com/investors/code-of-conduct-feb-2023.pdf 
• 
Vigil Mechanism: https://www.aartipharmalabs.com/
investors/vigil-mechanism-policy-feb-2023.pdf 
• 
Risk Management Policy: https://www.aartipharmalabs.
com/investors/APL_Risk%20Management%20Policy.pdf 
• 
Supplier Code of Conduct: https://www.aartipharmalabs.
com/files/supplier-code-of-conduct.pdf 
P2:
• 
Environment, Health, Safety and Sustainability (EHS&S) 
Policy: https://www.aartipharmalabs.com/files/hse-
policy-english.pdf 
• 
Quality Policy: https://www.aartipharmalabs.com/
assets/images/quality-policy-aarti-pharmalabs-2022.
pdf 
• 
Responsible Procurement Policy: https://www.
aartipharmalabs.com/files/responsible-procurement-
policy.pdf
P3:
• 
Environment, Health, Safety and Sustainability (EHS&S) 
Policy: https://www.aartipharmalabs.com/files/hse-
policy-english.pdf 
• 
Prevention of Sexual Harassment (PoSH) Policy: https://
www.aartipharmalabs.com/investors/prevention-of-
sexual-harrasment-policy.pdf 
• 
People Policy: https://www.aartipharmalabs.com/files/
people-policy.pdf 
P4:
• 
People Policy: https://www.aartipharmalabs.com/files/
people-policy.pdf 
• 
Corporate Social Responsibility (CSR) Policy: https://www.
aartipharmalabs.com/investors/csr-policy-feb-2023.pdf 
• 
Supplier Code of Conduct: https://www.aartipharmalabs.
com/files/supplier-code-of-conduct.pdf
Aarti Pharmalabs Limited
94
Disclosure Questions
P1
P2
P3
P4
P5
P6
P7
P8
P9
P5:
• 
Environment, Health, Safety and Sustainability (EHS&S) 
Policy: https://www.aartipharmalabs.com/files/hse-
policy-english.pdf 
• 
People Policy: https://www.aartipharmalabs.com/files/
people-policy.pdf 
• 
Code of Ethical Conduct: https://www.aartipharmalabs.
com/investors/code-of-conduct-feb-2023.pdf 
• 
Supplier Code of Conduct: https://www.aartipharmalabs.
com/files/supplier-code-of-conduct.pdf 
P6:
• 
Environment, Health, Safety and Sustainability (EHS&S) 
Policy: https://www.aartipharmalabs.com/files/hse-
policy-english.pdf 
• 
Supplier Code of Conduct: https://www.aartipharmalabs.
com/files/supplier-code-of-conduct.pdf 
P8:
• 
Corporate Social Responsibility (CSR) Policy: https://www.
aartipharmalabs.com/investors/csr-policy-feb-2023.pdf 
P9:
• 
Information Security Policy: https://www.aartipharmalabs.
com/investors/information-security-policy.pdf 
• 
Quality Policy: https://www.aartipharmalabs.com/
assets/images/quality-policy-aarti-pharmalabs-2022.
pdf 
2.	 Whether the entity has translated the policy into procedures. 
(Yes / No)
Yes, each department/function maintains its own set of 
procedures.
3.	 Do the enlisted policies extend to your   value chain 
partners? (Yes/No)
Yes, we have dedicated supplier code of conduct which covers 
all the appliable aspects under the BRSR principles.
P1
P2
P3
P4
P5
P6
P7
P8
P9
4. 	 Name of the national and international codes/certifications/
labels/standards (e.g. Forest Stewardship Council, 
Fairtrade, Rainforest Alliance, Trustea) standards (e.g. SA 
8000, OHSAS, ISO, BIS) adopted by your entity and mapped 
to each principle.
The national and international codes/certifications/labels/ 
standards are as follows:
• 
FDCA (Manufacturing License)
• 
FDA Maharashtra
• 
FDCA (GMP)
• 
Export Inspection Council
• 
ISO 9001:2015
• 
ISO 14001:2015
• 
ISO 45001:2018
• 
FSSAI
• 
FSSC 22000
• 
Star – K Kosher
Annual Report 2023-24
Corporate Overview
Statutory Reports
Financial Statements
95
1-31
32-115
116-256
Disclosure Questions
P1
P2
P3
P4
P5
P6
P7
P8
P9
• 
Jamiat Ulama Halal Foundation (Mumbai, India)
• 
Majelis Ulama (Halal) (Indonesia)
• 
SEDEX, SMETA (SMETA 4 pillar Certified Company)
• 
FDA (U.S Food and Drug Administration)
• 
UNGC India Network 
• 
EcoVadis 
5.	 Specific commitments, goals targets and performance by 
the entity with defined timelines, if any.
Not Applicable
6. 	 Performance of the entity against the specific 
commitments, goals, and targets along-with reasons in 
case the same are not met.
GOVERNANCE, LEADERSHIP AND OVERSIGHT
7.	 Statement by director responsible for the business 
responsibility report, highlighting ESG   related challenges, 
targets, and achievements (listed entity has flexibility 
regarding the placement of this disclosure)
Refer to the Managing Director’s message of the Annual report 
FY 2023-24.
8.	 Details of the highest authority responsible for 
implementation and oversight of the Business 
Responsibility policy(ies).
Smt. Hetal Gogri Gala, Vice Chairperson & Managing Director 
(DIN: 00005499) and Shri Narendra J. Salvi, Managing Director 
(DIN: 00299202) are responsible for implementation and 
oversight of the Business Responsibility policies.
9.	 Does the entity have a specified Committee of the Board/ 
Director responsible for decision making on sustainability 
related issues? (Yes/No). If yes, provide details.
At present, the Company does not have a dedicated Board-
level leader for sustainability-related issues. However, the CSR 
Committee oversees broader ESG aspects under the Board’s 
guidance.
10.	Details of Review of NGRBCs by the Company
Subject for Review
Indicate whether review was undertaken by Director / 
Committee of the Board/Any other Committee & Frequency
P1
P2
P3
P4
P5
P6
P7
P8
P9
Performance against above policies and follow up action
All policies outlined have been approved by the Board and 
Senior Management of the Company. To ensure compliance 
and effectiveness, we conduct regular internal audits and 
reviews of all policies and processes. This ongoing evaluation 
guarantees that our policies and procedures align with industry 
standards and best practices.
Compliance with statutory requirements of relevance to the 
principles and rectification of any non-compliances
The Company is in compliance with the extant regulations, as 
applicable.
11.	 Has the entity carried out independent assessment/ 
evaluation of the working of its policies by an external 
agency? (Yes/No). If yes, provide name of the agency
Yes, the Company has undertaken any third-party assessments 
of its policies however shall continue to take up internal 
assessments periodically to ensure smooth implementation 
of the policies.
We are in the process of undertaking independent third-party 
assurance for our sustainability performance. For the reporting 
year, the authenticity of the data and systems disclosed in our 
sustainability disclosures has been assured by an independent 
third-party assurance provider. This assurance was provided as 
per AA1000AS v3 ‘Type 2 - Moderate’ Assurance.
Additionally, relevant third-party assessments and certifications 
are periodically conducted across our business units.
Aarti Pharmalabs Limited
96
12.	  If answer to question (1) above is “No” i.e. not all Principles are covered by a policy, reasons to be stated: 
Questions
P1
P2
P3
P4
P5
P6
P7
P8
P9
The entity does not consider the principles   material to its 
business (Yes/No)
Not Applicable
The entity is not at a stage where it is in a position to formulate 
and implement the policies on specified principles (Yes/No)
The entity does not have the financial or/human and technical 
resources available for the task (Yes/No)
It is planned to be done in the next financial year (Yes/No)
Any other reason (please specify)
SECTION C: PRINCIPLE-WISE PERFORMANCE DISCLOSURE
PRINICPLE 1: BUSINESSES SHOULD CONDUCT AND GOVERN THEMSELVES WITH INTEGRITY AND IN A MANNER THAT IS 
ETHICAL, TRANSPARENT AND ACCOUNTABLE
Essential Indicators:
1.	
Percentage coverage by training and awareness programmes on any of the principles during the financial year
Segment
Total number 
of training and 
awareness 
programmes held
Topics/ principles covered under the 
training and its impact
% of persons in 
respective category 
covered by the 
awareness programmes
Board of directors
1
We regularly conduct familiarization 
programs for our Board of Directors, Key 
Managerial Personnel, Employees and 
Workers. These programs cover topics 
such as Code of conduct, anti-bribery and 
anti-corruption, human rights, health and 
safety as well as various other regulatory 
updates.
100%
Key Managerial Personnel
1
100%
Employees other than 
BOD and KMPs
1,159
80.57%
Workers
84.11%
* Training and awareness programmes for employees other than BoD and KMP, and workers were conducted collectively.
2.	
Details of fines / penalties /punishment/ award/ compounding fees/ settlement amount paid in proceedings (by the 
entity or by directors / KMPs) with regulators/ law enforcement agencies/ judicial institutions, in the financial year, in the 
following format (Note: the entity shall make disclosures on the basis of materiality as specified in Regulation 30 of SEBI 
(Listing Obligations and Disclosure Obligations) Regulations, 2015 and as disclosed on the entity’s website):
Monetary
NGRBC 
Principle
Name of the regulatory / enforcement 
agencies / judicial institutions
Amount
(`)
Brief of 
the Case
Has an appeal been 
preferred? (Yes/No)
Penalty/ Fine
NIL
Settlement
Compounding Fee
Non-Monetary
NGRBC 
Principle
Name of the regulatory/ enforcement 
agencies/ judicial Institutions
Brief of the Case
Has an appeal been 
preferred? (Yes/No)
Imprisonment
NIL
Punishment
3.	
Of the instances disclosed in Question 2 above, details of the appeal/revision preferred in cases where monetary or non-
monetary action has been appealed.
	
Not Applicable as there were no monetary and non-monetary cases recorded during the reporting period.
Annual Report 2023-24
Corporate Overview
Statutory Reports
Financial Statements
97
1-31
32-115
116-256
4.	
Does the entity have an anti-corruption or anti-bribery policy? If yes, provide details in brief and if available, provide a 
web-link to the policy.
	
APL has a comprehensive and well-defined Code of Conduct and Vigil Mechanism policy that places significant emphasis 
on anti-corruption and anti-bribery practices. The Company firmly believes that all employees must uphold the principles 
outlined in these policies, fulfilling their responsibilities with the utmost faith, discretion, and care, while maintaining the 
highest standards of honesty, integrity, and fairness. The policy strictly prohibits the use or promise of bribery or any other 
unfair advantage, whether directly or indirectly, to gain or secure benefits. For more details, refer to 
	
• 
Vigil mechanism Policy: https://www.aartipharmalabs.com/investors/vigil-mechanism-policy-feb-2023.pdf 
	
• 
Code of Conduct: https://www.aartipharmalabs.com/investors/code-of-conduct-feb-2023.pdf 
5.	
Number of Directors/KMPs/employees against whom disciplinary action was taken by any law enforcement agency for 
the charges of bribery/ corruption.
FY 2023-24
FY 2022-23
Directors
0
0
KMPs
0
0
Employees
0
0
Workers
0
0
6.	
Details of complaints with regard to conflict of interest
FY 2023-24
FY 2022-23
Number
Remarks
Number
Remarks
Number of complaints received in relation to issues of conflict 
of interest of directors
0
-
0
-
Number of complaints received in relation to issues of conflict 
of interest of KMPs
0
-
0
-
7.	
Provide details of any corrective action taken or underway on issues related to fines/penalties/action taken by regulators/
law enforcement agencies/judicial institutions, on cases of corruption and conflicts of interest.
	
Not Applicable as there were no fines or penalties reported during the reporting period.
8.	
Number of days of accounts payables ((Accounts payable *365) / Cost of goods/services procured) in the following format:
FY 2023-24
FY 2022-23
Number of days of accounts payables
83 days
58 days
9.	
Provide details of concentration of purchases and sales with trading houses, dealers, and related parties along-with 
loans and advances & investments, with related parties, in the following format:	
Parameter
Metrics
FY 2023-24
FY 2022-23
Concentration of 
Purchases
a.	
Purchases from trading houses as % of total purchases
13.94%
10.69%
b.	
Number of trading houses where purchases are made 
from
107
102
c.	
Purchases from top 10 trading houses as % of total 
purchases from trading houses
10.52%
8.08%
Concentration of 
Sales
a.	
Sales to dealers / distributors as % of total sales
20%
19.5%
b.	
Number of dealers / distributors to whom sales are 
made
90
85
c.	
Sales to top 10 dealers / distributors as % of total sales 
to dealers / distributors
10.73%
10.4%
Aarti Pharmalabs Limited
98
Parameter
Metrics
FY 2023-24
FY 2022-23
Share of RPTs in
a.	
Purchases (Purchases with related parties / Total 
Purchases)
16%
15%
b. 	
Sales (Sales to related parties / Total Sales)
6%
7%
c. 	
Loans & advances (Loans & advances given to related 
parties / Total loans & advances)
19%
25%
d.	
Investments (Investments in related parties / Total 
Investments made)
34%
38%
PRINICPLE 2: BUSINESSES SHOULD PROVIDE GOODS AND SERVICES IN A MANNER THAT IS SUSTAINABLE AND SAFE
Essential Indicators:
1.	
1.	
Percentage of R&D and capital expenditure (capex) investments in specific technologies to improve the environmental 
and social impacts of product and processes to total R&D and capex investments made by the entity, respectively.
FY 2023-24
FY 2022-23
Details of improvements in environmental and social impacts
R&D
7.35%
4.33 %
•	
Fume hoods for all laboratory
•	
Scrubbing Systems at new R&D
•	
Airflow monitoring system in fume hood
Capex
8.04%
13.90 %
•	
MVR setups in Effluent treatment plants
•	
Upgradation of unit operations in ETP by new technologies/equipment.
•	
Indirect Cooling system for reactors
•	
Procurements of Air-breathing apparatus at new projects before start up
2.	
a.	
Does the entity have procedures in place for sustainable sourcing? (Yes/No) - Yes
	
b.	
If yes, what percentage of inputs were sourced sustainably?
	
	
Yes, the company has established a robust responsible procurement policy which acts as a guiding force for APL to 
implement sustainable measures along its value chain. 48.72% of the key raw material suppliers were assessed.
3.	
Describe the processes in place to safely reclaim your products for reusing, recycling, and disposing at the end of life, for 
(a) Plastics (including packaging) (b) E-waste (c) Hazardous waste and (d) other waste.
	
APL adheres to the 3R principle—reduce, reuse, recycle—as a cornerstone of its waste management strategy, applied 
comprehensively across all operations to address every type of waste generated. Our facilities are equipped with robust 
waste management systems to support this commitment. We prioritize minimizing waste generation, promoting material 
reuse, and ensuring efficient recycling processes to conserve resources sustainably.
	
A. 	 Plastic Waste: All plastic waste is directed to authorized recyclers for further processing.
	
B. 	
E-Waste: Generated e-waste undergoes safe disposal at authorized recycling facilities.
	
C. 	 Hazardous Waste: Hazardous waste is managed according to regulatory guidelines, including disposal at CHWTSDF 
sites for landfill or incineration. Some categories are sent to authorized recyclers as per consent conditions outlined 
in the Hazardous and Other Waste (M & TM) Rules, 2016. Recently, APL obtained consent to send hazardous waste 
to an authorized pre-processor and coprocessor, advancing responsible waste management practices.
4.	
Whether Extended Producer Responsibility (EPR) is applicable to the entity’s activities (Yes / No). If yes, whether the 
waste collection plan is in line with the Extended Producer Responsibility (EPR) plan submitted to Pollution Control 
Boards? If not, provide steps taken to address the same.
	
Yes, APL’s waste collection plan aligns with the Extended Producer Responsibility (EPR) plan. The company has received 
its EPR targets from the Central Pollution Control Board (CPCB), and activities related to EPR implementation are currently 
underway. APL is registered with CPCB for EPR compliance, demonstrating its commitment to responsible environmental 
stewardship.
Annual Report 2023-24
Corporate Overview
Statutory Reports
Financial Statements
99
1-31
32-115
116-256
PRINCIPLE 3: BUSINESSES SHOULD RESPECT AND PROMOTE THE WELL-BEING OF ALL EMPLOYEES, INCLUDING THOSE IN 
THEIR VALUE CHAINS
Essential Indicators
1.	
A.	
Details of measures for the well-being of employees
Category
% of employees covered by
Total 
(A)
Health  
insurance
Accident 
insurance
Maternity benefits
Paternity  
Benefits
Day Care 
facilities
No.  
(B)
% 
 (B/A)
No.  
(C)
%  
(C / A)
No.  
 (D
%  
(D / A
No.  
 (E)
%  
(E / A)
No.  
(F)
%  
(F / A)
PERMANENT EMPLOYEES
Male
1,543
1,543
100.00%
1,543
100.00%
0
0.00%
0
0%
0
0.00%
Female
84
84
100.00%
84
100.00%
84
100.00%
0
0%
0
0.00%
Total
1,627
1,627
100.00%
1,627
100.00%
84
100.00%
0
0%
0
0.00%
OTHER THAN PERMANENT EMPLOYEES
Male
67
2
2.98%
67
100.00%
0
0.00%
0
0.00%
0
0.00%
Female
20
0
0.00%
20
100.00%
20
100.00%
0
0.00%
0
0.00%
Total
87
2
2.29%
87
100.00%
20
22.98%
0
0.00%
0
0.00%
	
b.	
Details of measures for the well-being of workers:
Category
% of employees covered by
Total 
(A)
Health  
insurance
Accident 
insurance
Maternity  
benefits
Paternity  
Benefits
Day Care  
facilities
No.  
(B)
%  
(B / A
No.  
 (C)
%  
(C / A)
No.  
 (D
%  
(D / A
No.  
 (E)
%  
(E / A)
No.  
 (F)
%  
(F / A)
PERMANENT WORKERS
Male
468
468
100.00%
468
100.00%
0
0.00%
0
0.00%
0
0.00%
Female
0
0
0.00%
0
0.00%
0
0.00%
0
0.00%
0
0.00%
Total
468
468
100.00%
468
100.00%
0
0.00%
0
0.00%
0
0.00%
OTHER THAN PERMANENT WORKERS
Male
994
0
0.00%
994
100.00%
0
0.00%
0
0.00%
0
0.00%
Female
7
0
0.00%
7
100.00%
7
100.00%
0
0.00%
0
0.00%
Total
1,001
0
0.00%
1,001
100.00%
7
0.70%
0
0.00%
0
0.00%
	
C.	
Spending on measures towards well-being of employees and workers (including permanent and other than permanent) 
in the following format
FY 2023-24
FY 2022-23
Cost incurred on well-being measures as a % of total revenue of the company
1%
1%
Aarti Pharmalabs Limited
100
2.	
Details of retirement benefits for the current and previous financial year
Benefits
FY 2023-24
FY 2022-23
No. of employees 
covered as a % of 
total employees
No. of workers 
covered as 
a % of total 
employees
Deducted and 
deposited with 
the authority 
(Y/N/N.A.) *
No. of employees 
covered as a % of 
total employees
No. of workers 
covered as 
a % of total 
employees
Deducted and 
deposited with 
the authority 
(Y/N/N.A.)
PF
90.43%
67.99%
Y
100%
100%
Y
Gratuity
94.92%
67.99%
Y
100%
100%
Y
Employee 
State 
Insurance (ESI)
11.90%
100%
Y
100%
100%
Y
3.	
Accessibility of workplaces: Are the premises/offices accessible to differently abled employees as per the requirements 
of the Rights of Persons with Disabilities Act, 2016? If not, whether any steps are being taken by the entity in this regard.
	
APL’s offices have been well equipped with accessibility measures such as rails, ramps and wheelchairs to facilitate the 
movement of differently-abled employees in accordance with the Rights of Persons with Disabilities Act, 2016.
4.	
Does the entity have an equal opportunity policy as per the Rights of Persons with Disabilities Act, 2016? If so, provide a 
web-link to the policy.
	
Yes; the entity has laid out the necessary provisions in the HR Policy in line with the Rights of Persons with Disabilities 
Act, 2016. The Company ensures compliance of 100% employee related applicable statutes which ensures social security. 
For more details https://www.aartipharmalabs.com/responsible-workforce 
5.	
Return to work and retention rates of permanent employees that took parental leave.
Permanent employees
Gender
Return to work rate 
Retention rate
Male
NA
NA 
Female
100%
80%
Total
100%
80%
6.	
Is there a mechanism available to receive and redress grievances for the following categories of employees? If yes, give 
details of the mechanism in brief.
Yes/No  
(If yes, then give details of the mechanism in brief)
Permanent Employees
Yes
Other than Permanent Employees
Yes
Permanent Workers
Yes
Other than Permanent Workers
Yes
	
APL has established a Vigil Mechanism policy that defines the grievance mechanisms for employees and workers. For more 
details, refer to Vigil mechanism Policy: https://www.aartipharmalabs.com/investors/vigil-mechanism-policy-feb-2023.
pdf
Annual Report 2023-24
Corporate Overview
Statutory Reports
Financial Statements
101
1-31
32-115
116-256
7.	
Membership of employees in association(s) or unions
Category
FY 2023-24
FY 2022-23
No. of 
employees 
covered as 
a % of total 
employees (A)
No. of employees / 
workers in respective 
category, who are 
part of association(s) 
or Union (B)
%  
(B / A)
Total 
employees 
/ workers in 
respective 
category (C)
No. of employees / 
workers in respective 
category, who are 
part of association(s) 
or Union (D)
%  
(D / C)
Total Permanent 
Employees
1,627
0
0.00%
1,400
0
0.00%
Male
1,543
0
0.00%
1,328
0
0.00%
Female
84
0
0.00%
72
0
0.00%
Total Permanent 
Workers
468
140
29.91%
642
125
19%
Male
468
140
29.91%
642
125
19%
Female
0
0
0.00%
0
0
0%
8.	
Details of training given to employees
Category
FY 2023-24
FY 2022-23
Total 
(A
On health and safety/
wellness measures
On skill  
upgradation
Total 
(A)
On health and safety 
measures/ wellness
On Skill 
upgradation
No. (B)
% (B / A)
No. (C)
% (C / A)
No. (B)
% (B/A)
No. (C)
% (C/A)
EMPLOYEES
Male
1,610
1,316
81.74%
1,162
72.17%
1,328
1,328
100%
1,195
90%
Female
104
62
59.61%
65
62.5%
72
72
100%
52
72%
Total
1,714
1,378
80.40%
1,227
71.58%
1,400
1,400
100%
1,247
89%
WORKERS
Male
1462
210
14.36%
490
33.51%
642
642
100%
642
100%
Female
7
3
42.85%
2
28.57%
0
0
0%
0
0%
Total
1,469
213
14.49%
492
33.49%
642
642
100%
642
100%
9.	
Details of performance and career development reviews* of employees
Category
FY 2023-24
FY 2022-23
Total (A)
No. (B)
% (B / A)
Total (C)
No. (D)
% (D / C)
EMPLOYEES
Male
1,529
1,316
86.07%
1,328
1,135
85%
Female
85
66
77.65%
72
56
77%
Total
1,614
1,382
85.62%
1,400
1,191
85%
Workers
Male
468
458
97.86%
642
606
94%
Female
0
0
0
0
0
0%
Total
468
458
97.86%
642
606
94%
10.	 Health and safety management system
	
a.	
Whether an occupational health and safety management system has been implemented by the entity? (Yes/ No). If 
yes, the coverage of such system? 
	
	
Yes, APL maintains an ISO 45001 certified occupational health and safety management system. The company is 
dedicated to continually improving its safety protocols to achieve a zero-incidence goal. A detailed Health, Safety, 
and Environment (HSE) manual reinforces the group’s “Safety first” legacy, ensuring comprehensive coverage across 
all operations. APL conducts extensive training and awareness programs to prevent unsafe working conditions and 
mitigate potential risks, encompassing both employees and contractors with a 100% coverage rate.
Aarti Pharmalabs Limited
102
	
b.	
What are the processes used to identify work -related hazards and assess risks on a routine and non-routine basis 
by the entity?
	
	
To identify and assess work-related hazards and risks, APL conducts periodic meetings involving all operational safety 
personnel. The company’s ISO 45001:2018 certification ensures adherence to comprehensive safety standards and 
protocols, aimed at achieving operational excellence. APL also conducts regular safety trainings and assessments to 
ensure employee welfare.
	
	
Routine safety measures include Hazard Identification and Risk Assessment (HIRA), HAZOP (for process deviation), 
what-if analysis, hazard checklists, and Quantitative Risk/Impact Assessment (QRA) during project stages. For non-
routine work, APL utilizes Job Safety Analysis (JSA) to enhance safety protocols and mitigate potential risks effectively.
	
c.	
Whether you have processes for workers to report the work-related hazards and to remove themselves from such 
risks. (Y/N) 
	
	
Yes, Aarti Pharmalabs Limited has implemented various modules following APMS guidelines to enhance safety and 
enable workers to report work-related hazards effectively. These modules include General Plant Condition, Unsafe Acts, 
Unsafe Conditions, Near Miss reporting, Behaviour Based Safety, and Tool Box Talks. Reports are submitted through 
the INTELEX module or via the G-suite platform. The company prioritizes social security and maintains a proactive 
approach to ensuring a safe working environment for all.
	
d.	
Do the employees have access to non-occupational medical and healthcare services? (Yes/ No)
	
	
Yes, APL provides coverage for its employees and workers through a Group Term Life Insurance Policy. The company 
has partnered with hospitals that offer visiting doctors to provide non-occupational healthcare services. Additionally, 
APL runs a vaccination program aimed at preventing contagious diseases such as Hepatitis B and tetanus among 
its workforce.
11.	 Details of safety related incidents
Safety Incident/Number
Category
FY 2023-24
FY 2022-23
Lost Time Injury Frequency Rate (LTIFR) (per one million-
person hours worked)
Employees
0.00
0.42
Workers
 0.32
 0.31
Total recordable work-related injuries
Employees
0
2
Workers
1
1
No. of fatalities (safety incident)
Employees
0
0
Workers
0
0
High consequence work-related injury or ill-health 
(excluding fatalities)
Employees
0
0
Workers
0
0
12.	 Describe the measures taken by the entity to ensure a safe and healthy workplace.
	
Aarti Pharmalabs Limited has developed a comprehensive Health, Safety, and Environment (HSE) policy aimed at ensuring a 
secure and healthy workplace for all individuals. The company is committed to compliance with the Factory Act of 1948. To 
enhance process safety, APL implements hazard checklists and conducts regular Hazard and Operability Studies (HAZOP) 
at its facilities. A dedicated process safety laboratory actively identifies potential hazards associated with both new and 
existing processes.
	
In line with the APMS (Aarti Pharmalabs Management System) guidelines, APL adopts various measures including the 
Permit system, General Plant Condition assessments, Management of Change protocols, and Pre Start-up Safety Reviews 
to uphold safety standards. Advanced scrubbing systems and air ventilation systems are installed across sites to mitigate 
workplace exposures.
	
APL has also instituted an Industrial Hygiene program to identify operations that could pose hazardous exposures. Regular 
medical check-ups are conducted for employees and contract workers, supported by trained medical personnel onsite to 
handle work-related emergencies. The company ensures the availability of necessary and specialized Personal Protective 
Equipment (PPE) tailored to specific operations. Additionally, APL provides compensation for accidents or mishaps to 
prioritize the well-being of its workforce.
Annual Report 2023-24
Corporate Overview
Statutory Reports
Financial Statements
103
1-31
32-115
116-256
13.	 Number of complaints on the following made by employees
FY 2023-24
FY 2022-23
Filed during 
the year
Pending resolution at 
the end of year
Remarks
Filed during 
the year
Pending resolution at 
the end of year
Remarks
Working 
conditions
0
0
-
0
0
-
Health and 
safety
0
0
-
0
0
-
14.	 Assessments for the year.
% of your plants and offices that were assessed  
(by entity or statutory authorities or third parties)
Health and safety practices
100%
Working Conditions
100%
15.	 Provide details of any corrective action taken or underway to address safety-related incidents (if any) and on significant 
risks / concerns arising from assessments of health and safety practices and working conditions.
	
We have a well-established procedure where an Environmental, Health, and Safety (EHS) assessment is conducted 
before undertaking any project. Currently, there are no significant risks/concerns identified from the health and safety 
assessments.
PRINCIPLE 4: BUSINESSES SHOULD RESPECT THE INTERESTS OF AND BE RESPONSIVE TO ALL ITS STAKEHOLDERS
Essential Indicators
1.	
Describe the processes for identifying key stakeholder groups of the entity.
	
At APL, our key stakeholders encompass customers, investors, board members, employees, clients, suppliers, the 
community, and regulators, among others. We prioritize building trust and fostering collaborative relationships with these 
stakeholders, believing it is integral to our success. Effective communication with stakeholders forms a cornerstone of 
our strategy. Over the years, we have nurtured strong relationships based on trust and mutual respect. Through regular 
engagement across various channels, we actively listen to their needs and aspirations, ensuring our initiatives align closely 
with their expectations.
2.	
List stakeholder groups identified as key for your entity and the frequency of engagement with each stakeholder group.
Key Stakeholders
Whether 
identified as 
Vulnerable & 
Marginalized 
Group (Yes/No)
Channels of communication 
(Email, SMS, Newspaper, 
Pamphlets, Advertisement, 
Community Meetings, Notice 
Board, Website), Others
Frequency of 
engagement 
(Annually/Half 
yearly/ Quarterly
/ Others – please 
specify)
Purpose and scope of 
engagement including 
key topics and concerns 
raised during such 
engagement
Board and Committees
No
Presentations, reports, 
surveys, awareness sessions
Quarterly and as 
needed
Oversight of operations, 
business performance, 
risks and opportunities, 
strategy alignment, ESG 
initiatives, compliance, 
and crisis management.
Employees and Workers
No
Email, website, notice boards, 
training sessions, surveys
Daily
Engagement to foster a 
safe, inclusive workplace, 
provide updates on 
company and industry 
developments, encourage 
feedback and innovation, 
and support professional 
growth.
Aarti Pharmalabs Limited
104
Key Stakeholders
Whether 
identified as 
Vulnerable & 
Marginalized 
Group (Yes/No)
Channels of communication 
(Email, SMS, Newspaper, 
Pamphlets, Advertisement, 
Community Meetings, Notice 
Board, Website), Others
Frequency of 
engagement 
(Annually/Half 
yearly/ Quarterly
/ Others – please 
specify)
Purpose and scope of 
engagement including 
key topics and concerns 
raised during such 
engagement
Suppliers
No
Supplier audits, meetings, 
topic-based engagement
Frequent and as 
needed
Ensure business 
continuity, quality 
compliance, address ESG 
parameters, and resolve 
product-related issues 
and feedback.
Customers
No
Customer meetings, 
audits, surveys, structured 
engagements
Frequent
Enhance market share, 
introduce new products, 
ensure fair business 
practices, and address 
customer feedback and 
queries.
Government and 
Regulators
No
Submissions, meetings, 
emails, website
Need-based
Compliance with 
regulations, facilitate 
product development 
and manufacturing, and 
uphold high standards of 
operational compliance.
Community
Yes
Physical visits, digital 
channels
Frequent and as 
needed
Support sustainable 
development, address 
local community 
needs, focus on health, 
education, gender 
equality, afforestation, 
and infrastructure 
development.
Investors/Financial 
Partners
No
Investor meetings, 
conferences, earnings calls, 
press releases
Frequent and as 
needed
Provide updates on 
financial performance, 
strategic direction, 
sustainability goals, 
and significant events 
impacting the company's 
performance.
Annual Report 2023-24
Corporate Overview
Statutory Reports
Financial Statements
105
1-31
32-115
116-256
PRINCIPLE 5: BUSINESSES SHOULD RESPECT AND PROMOTE HUMAN RIGHTS
Essential Indicators
1.	
Employees who have been provided training on human rights issues and policy(ies) of the entity, in the following format
Category
FY 2023-24
FY 2022-23
Total 
(A)
No. of employees 
covered (B)
%  
(B / A)
Total 
(C)
No. of employees 
covered (D)
%  
(D / C)
EMPLOYEES
Permanent
1,627
1,347
82.79%
1,400
885
63.21%
Other than permanent
87
0
0.00%
0
0
0%
Total Employees
1,714
1,347
78.58%
1,400
885
63.21%
WORKERS
Permanent
468
467
99.78%
642
389
60.59%
Other than permanent
994
0
0.00%
866
433
50%
Total Workers
1,001
467
46.65%
1,508
822
54.5%
2.	
Details of minimum wages paid to employees
Category
FY 2023-24
FY 2022-23
Total 
(A)
Equal to Minimum 
Wage
More than Minimum 
Wage
Total 
(D)
Equal to Minimum 
Wage
More than Minimum 
Wage
No. (B)
% (B / A)
No. (C)
% (C / A)
No. (E)
% (E / D)
No. (F)
% (F / D)
EMPLOYEES
Permanent
1,627
0
0
1,627
100%
1,400
0
0
1,400
100%
Male
1,543
0
0.00%
1,543
100.00%
1,328
0
0%
1,328
100%
Female
84
0
0.00%
84
100.00%
72
0
0%
72
100%
Other than 
Permanent
0
0
0
0
0%
0
0
0
0
0%
Male
0
0
0
0
0%
0
0
0
0
0%
Female
0
0
0
0
0
0
0
0
0
0
WORKERS
Permanent
468
0
0.00%
468
100.00%
642
0
0%
642
100%
Male
468
0
0.00%
468
100.00%
642
0
0%
642
100%
Female
0
0
0.00%
0
0.00%
0
0%
0
0%
0
Other than 
Permanent
1,001
1,001
100%
0
0%
886
886
100%
0
0
Male
994
994
100.00%
0
0.00%
886
886
100%
0
0%
Female
7
7
100.00%
0
0.00%
0
0
0%
0
0%
3.	
A.	
Details of remuneration/salary/Wages, in the following format:
Male
Female
Number
Median remuneration/ 
salary/ wages of respective 
category (₹ Lakhs)
Number
Median remuneration/ 
salary/ wages of respective 
category (₹ Lakhs)
Board of Directors (BoD) 
(including whole-time directors)
1
Refer to Director’s Report of 
our Annual Report  
FY 2023-24
1
Refer to Director’s Report of 
our Annual Report  
FY 2023-24
Key Managerial Personnel (other 
than BoD)
2
0
Employees other than BoD and 
KMP*
1,544
5.04
83
3.86
Workers
468
4.17
0
0
Aarti Pharmalabs Limited
106
	
B.	
Gross wages paid to females as % of total wages paid by the entity, in the following format:
FY 2023-24
FY 2022-23
Gross wages paid to females as % of total wages
3%
3%
4.	
Do you have a focal point (Individual/ Committee) responsible for addressing human rights impacts or issues caused or 
contributed to by the business? (Yes/No)
	
Yes, Aarti Pharmalabs Limited is deeply committed to upholding and promoting high standards of human rights across 
all its operations. The Works Council plays a pivotal role in ensuring strict adherence to these principles as part of the 
company’s corporate responsibility framework.
	
APL prioritizes the dignity and individual rights of every employee, worker, and external stakeholder engaged in its business 
activities. The company is steadfast in its commitment to ensuring that none of its operations compromise the human 
rights of its valued stakeholders. APL aims to cultivate a respectful and inclusive environment that enhances overall well-
being within the organization.
5.	
Describe the internal mechanisms in place to redress grievances related to human rights issues
	
Aarti Pharmalabs Limited prioritizes the well-being and rights of all individuals associated with the company. The company 
has implemented a robust grievance redressal mechanism aimed at promptly and effectively addressing any human rights 
issues that may arise. APL fosters open communication and provides multiple channels for employees and stakeholders 
to report concerns or seek assistance.
	
A dedicated team is responsible for thoroughly investigating and resolving grievances in a fair and impartial manner, 
ensuring confidentiality throughout the process. APL is committed to continuously enhancing its grievance redressal 
process to maintain a safe and respectful environment for everyone involved.
6.	
Number of complaints on the following made by employees and workers
FY 2023-24
FY 2022-23
Filed during 
the year
Pending 
resolution at the 
end of the year
Remarks
Filed during 
the year
Pending 
resolution at the 
end of the year
Remarks
Sexual Harassment
0
0
-
0
0
-
Discrimination at 
workplace
0
0
-
0
0
-
Child Labour
0
0
-
0
0
-
Forced Labour/ 
Involuntary Labour
0
0
-
0
0
-
Wages
0
0
-
0
0
-
Other human rights related 
issues
0
0
-
0
0
-
7.	
Complaints filed under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 
2013, in the following format
FY 2023-24
FY 2022-23
Total Complaints reported under Sexual Harassment on of Women at 
Workplace (Prevention, Prohibition and Redressal) Act, 2013 (POSH)
0
0
Complaints on POSH as a % of female employees / workers
0
0
Complaints on POSH upheld
0
0
Annual Report 2023-24
Corporate Overview
Statutory Reports
Financial Statements
107
1-31
32-115
116-256
8.	
Mechanisms to prevent adverse consequences to the complainant in discrimination and harassment cases
	
Aarti Pharmalabs Limited maintains a zero-tolerance policy towards any form of sexual harassment in the workplace. To 
address this issue effectively, the company has implemented a comprehensive grievance resolution procedure under its 
Prevention of Sexual Harassment (POSH) policy. APL has established a stringent Code of Conduct and HR Policy Manual 
that clearly outline expectations for appropriate employee behavior and provide measures for preventing and addressing 
complaints.
	
All employees, including new joiners, undergo PoSH training not only during induction but also at regular intervals 
throughout their tenure at APL. This training ensures awareness and understanding of the company’s policies and 
procedures regarding sexual harassment prevention and redressal.
	
To ensure prompt and confidential resolution of complaints, APL has formed an Internal Complaints Committee dedicated 
to monitoring and addressing harassment complaints. This committee is tasked with taking appropriate actions in a timely 
manner while upholding strict confidentiality.
9.	
Do human rights requirements form part of your business agreements and contracts?
	
Yes; At APL, all the business agreements and contracts carry the clauses of human rights for promoting sustainable, fair 
and equitable competition for all its stakeholders.
10.	 Assessments for the year
% of offices that were assessed  
(by entity or statutory authorities or third parties)
Child labour
45%
Forced/involuntary labour
Sexual harassment
Discrimination at workplace
Wages
11.	 Provide details of any corrective actions taken or underway to address significant risks / concerns arising from the 
assessments at Question 9 above.
	
There were no significant risks/concerns from the social assessment conducted.
PRINCIPLE 6: BUSINESSES SHOULD RESPECT AND MAKE EFFORTS TO PROTECT AND RESTORE THE ENVIRONMENT
Essential Indicators
1.	
Details of total energy consumption (in Joules or multiples) and energy intensity
Parameter
FY 2023-24
FY 2022-23
From renewable sources
Total electricity consumption (A) 
0
0
Total fuel consumption (B) 
0
0
Energy consumption through other sources (C) 
0
0
Total energy consumed from renewable sources (A+B+C) 
0
0
From non-renewable sources
Total electricity consumption (D) GJ
2,87,347.98
2,50,463.13
Total fuel consumption (E) GJ
8,64,831.57
5,37,025.99
Energy consumption through other sources (F) GJ
1,31,548.79
0
Aarti Pharmalabs Limited
108
Parameter
FY 2023-24
FY 2022-23
Total energy consumed from non-renewable sources (D+E+F) GJ 
 12,83,728.34 
 7,87,489.12 
Total energy consumed (A+B+C+D+E+F) GJ
 12,83,728.34 
 7,87,489.12 
Energy intensity per rupee of turnover (Total energy consumed / Revenue from 
operations)
 0.000085
 0.000052
Energy intensity per rupee of turnover adjusted for Purchasing Power Parity 
(PPP)*  (Total energy consumed / Revenue from operations adjusted for PPP) 
 0.001914
 0.001155
Energy intensity in terms of physical output (GJ/Tonne)
46.25
31.55
	
* PPP – IMF conversion factors for FY 2023-24: 22.4 and FY 2022-23: 22.17
	
(Source - https://www.imf.org/external/datamapper/PPPEX@WEO/OEMDC/IND)
	
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? If yes, 
name of the external agency. - Yes, SustainEDGE Business Solutions Private Limited, a third party conducts an annual 
assurance on sustainability parameters reported in the Sustainability report of the Company. The assurance is performed 
for 2023-2024.
2.	
Does the entity have any sites / facilities identified as designated consumers (DCs) under the Performance, Achieve and 
Trade (PAT) Scheme of the Government of India? (Y/N) If yes, disclose whether targets set under the PAT scheme have 
been achieved. In case targets have not been achieved, provide the remedial action taken, if any.   
	
Not applicable	
3.	
Provide details of the following disclosures related to water.
Safety Incident/Number
FY 2023-24
FY 2022-23
Water withdrawal by source (in kilolitres)
(i)	
Surface Water
-
-
(ii)	 Ground Water
-
-
(iii)	 Third Party Water
3,91,904
4,04,898
(iv) 	 Seawater / desalinated water
-
-
(v) 	 Others
-
-
Total volume of water withdrawal (in kilolitres) (i + ii + iii + iv + v)
3,91,904
4,04,898
Total volume of water consumption (in kilolitres)
3,91,904
4,04,898
Water intensity per rupee of turnover (Total water consumption / Revenue 
from operations)
 0.00002609 
 0.00002679 
Water intensity per rupee of turnover adjusted for Purchasing Power Parity 
(PPP)* (Total water consumption / Revenue from operations adjusted for 
PPP) 
 0.000584 
 0.000594 
Water intensity in terms of physical output (KL/Tonne)
14.12
16.22
	
* PPP – IMF conversion factors for FY 2023-24: 22.4 and FY 2022-23: 22.17
	
(Source - https://www.imf.org/external/datamapper/PPPEX@WEO/OEMDC/IND)
	
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If 
yes, name of the external agency. - Yes, SustainEDGE Business Solutions Private Limited, a third party conducts an annual 
assurance on sustainability parameters reported in the Sustainability report of the Company. The assurance is performed 
for 2023-2024.
Annual Report 2023-24
Corporate Overview
Statutory Reports
Financial Statements
109
1-31
32-115
116-256
4.	
Provide the following details related to water discharged:
Parameter
FY 2023-24
FY 2022-23
Water discharge by destination and level of treatment (in kilolitres)
(i) 	
To Surface water 
-
-
- No treatment 
-
-
- With treatment – please specify level of treatment 
-
-
(ii)	
To Groundwater 
-
-
- No treatment 
-
-
- With treatment – please specify level of treatment 
-
-
(iii) 	 To Seawater 
-
-
- No treatment 
-
-
- With treatment – please specify level of treatment 
-
-
(iv) 	 Sent to third parties 
-
-
- No treatment 
-
-
- With treatment – please specify level of treatment 
-
-
(v) 	
Others 
-
-
- No treatment 
-
-
- With treatment – please specify level of treatment 
-
-
Total water discharged (in kilolitres) 
-
-
5.	
Has the entity implemented a mechanism for Zero Liquid Discharge? If yes, provide details of its coverage and 
implementation.
	
Yes, Aarti Pharmalabs Limited (APL) has implemented a comprehensive mechanism to achieve Zero Liquid Discharge (ZLD) 
across all its units. The company ensures 100% recycling of liquid waste generated and has established the necessary 
infrastructure and systems to comply with ZLD conditions specified by the Consent to Operate (CTO) requirements. This 
commitment highlights APL’s dedication to sustainable practices and responsible waste management.
6.	
Please provide details of air emissions (other than GHG emissions) by the entity.
Parameter
Specify Unit
FY 2023-24
FY 2022-23
NOx
tons
122.83
88.83
SOx
tons
320.44
380.23
Particulate matter (PM)
tons
361.38
386.47
Persistent organic pollutants (POP)
-
-
-
Volatile organic compounds (VOC)
-
-
-
Hazardous air pollutants (HAP)
-
-
-
Others – please specify
-
-
-
	
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If 
yes, name of the external agency. - Yes, SustainEDGE Business Solutions Private Limited, a third party conducts an annual 
assurance on sustainability parameters reported in the Sustainability report of the Company. The assurance is performed 
for 2023-2024.
7.	
Does the entity have any project related to reducing Green House Gas emission? If yes, then provide details.
Parameter
Unit
FY 2023-24
FY 2022-23
Total Scope 1 emissions (Break-up of the GHG into CO2, 
CH4, N2O, HFCs, PFCs, SF6, NF3, if available)
Metric tonnes of 
CO2 equivalent
88,101.32
37,390
Total Scope 2 emissions (Break-up of the GHG into CO2, 
CH4, N2O, HFCs, PFCs, SF6, NF3, if available)
Metric tonnes of 
CO2 equivalent
95,764.46
79,746
Total Scope 1 and Scope 2 emissions per rupee of turnover Metric tonnes of 
CO2 equivalent per 
Rupee
 0.00001224 
 0.00000775 
Aarti Pharmalabs Limited
110
Parameter
Unit
FY 2023-24
FY 2022-23
Total Scope 1 and Scope 2 emission intensity per rupee 
of turnover adjusted for Purchasing Power Parity (PPP)* 
(Total Scope 1 and Scope 2 GHG emissions / Revenue 
from operations adjusted for PPP)
Metric tonnes of 
CO2 equivalent per 
Rupee
 0.000274 
 0.000172 
Total Scope 1 and Scope 2 emission intensity in terms of 
physical output 
Metric tonnes of 
CO2 equivalent 
per tonne of 
production
6.62
4.69
	
* PPP – IMF conversion factors for FY 2023-24: 22.4 and FY 2022-23: 22.17
	
(Source - https://www.imf.org/external/datamapper/PPPEX@WEO/OEMDC/IND)
	
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If 
yes, name of the external agency - Yes, SustainEDGE Business Solutions Private Limited, a third party conducts an annual 
assurance on sustainability parameters reported in the Sustainability report of the Company. The assurance is performed 
for 2023-2024.
8.	
Does the entity have any project related to reducing Green House Gas emission? If yes, then provide details.
	
Yes, a solar energy project is currently underway in the Akola district of Maharashtra. This initiative is part of Aarti 
Pharmalabs Limited’s commitment to sustainable energy solutions. The project aims to harness solar power to reduce 
the company’s carbon footprint and promote renewable energy usage. The installation is progressing well and is expected 
to be completed by December 2024. Once operational, this solar energy project will significantly contribute to the region’s 
clean energy generation, aligning with APL’s broader environmental goals.
9.	
Provide details related to waste management by the entity, in the following format:
Parameter (in metric tonnes)
FY 2023-24
FY 2022-23
Total Waste generated (in metric tonnes)
Plastic waste (A)
98.48
72.66
E-waste recycled (B)
1.72
2.13
Bio-medical waste (C)
0.80
0.19
Construction and demolition waste (D)
0.00
17.5
Battery waste (E)
4.44
1.22
Radioactive waste (F)
0.00
0
Other Hazardous waste. Please specify, if any. (G)
12,702.62
4,770.32
Other Non-hazardous waste generated (H). Please specify, if any. (Break-up 
by composition i.e. by materials relevant to the sector)
868.28
873.94
Total (A+B + C + D + E + F + G + H)
13,676.33
5,737.96
Waste intensity per rupee of turnover (Total waste generated / Revenue from 
operations)
 0.00000091 
 0.00000038 
Annual Report 2023-24
Corporate Overview
Statutory Reports
Financial Statements
111
1-31
32-115
116-256
Parameter (in metric tonnes)
FY 2023-24
FY 2022-23
Waste intensity per rupee of turnover adjusted for Purchasing Power Parity 
(PPP)* (Total waste generated / Revenue from operations adjusted for PPP)
 0.000020 
 0.000008 
Waste intensity in terms of physical output  (Tonne/Tonne of Production)
0.49
0.23
For each category of waste generated, total waste recovered through recycling, re-using or other recovery operations 
(in metric tonnes)
Category of waste
(i) Recycled
3,072.52
2,004.71
(ii) Re-used
0.32
4051.84
(iii) Other recovery operations
0
0
Total
3,072.84
6,056.55
For each category of waste generated, total waste disposed by nature of disposal method (in metric tonnes)
Category of waste
(i) Incineration
1,091.89
545.27
(ii) Landfilling
9,429.03
8,472.9
(iii) Other disposal operations
0
0
Total
10,520.92
9,018.17
	
* PPP – IMF conversion factors for FY 2023-24: 22.4 and FY 2022-23: 22.17
	
(Source - https://www.imf.org/external/datamapper/PPPEX@WEO/OEMDC/IND)
	
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If 
yes, name of the external agency. - Yes, SustainEDGE Business Solutions Private Limited, a third party conducts an annual 
assurance on sustainability parameters reported in the Sustainability report of the Company. The assurance is performed 
for 2023-2024.
10.	 Briefly describe the waste management practices adopted in your establishments. Describe the strategy adopted by your 
company to reduce usage of hazardous and toxic chemicals in your products and processes and the practices adopted 
to manage such wastes.
	
APL has established a robust waste management system focused on environmental sustainability and responsible disposal 
practices. The company acknowledges the critical importance of reducing the environmental impact of its operations and 
efficiently managing the waste produced during its processes.
	
APL’s waste management strategy is crafted to meet the highest industry standards and regulatory requirements. The 
company employs a systematic approach to identify, segregate, handle, treat, and dispose of waste in an environmentally 
safe manner. APL’s objectives include minimizing waste generation, promoting recycling and reuse, and ensuring the 
proper disposal of hazardous waste.
	
•	
Green Chemistry Integration: During product design, APL integrates hazard checklists that adhere to green chemistry 
principles. The primary aim is to eliminate the use of toxic chemicals and design processes that reduce or entirely 
eliminate the production of hazardous waste. This approach follows a hierarchy of controls, actively seeking alternative 
materials and methods to decrease the use of harmful substances and minimize hazardous waste production.
	
•	
Innovative By-Product Treatment: In one of its product chains, APL has developed a specialized process to treat 
by-products and convert them into valuable resources. This innovative method significantly reduces environmental 
impact and supports sustainable practices.
	
•	
Emission Management: To manage emissions, APL’s plants are equipped with advanced scrubber systems that 
effectively capture emissions and prevent their release into the environment.
	
•	
Wastewater Management: For wastewater management, APL has installed advanced treatment plants and water 
Aarti Pharmalabs Limited
112
recovery units employing technologies such as reverse osmosis (RO), multiple-effect evaporators (MEEs), and 
agitated thin film dryers (ATFD). These systems allow the recovery and reuse of water from wastewater streams. 
Recently, APL has adopted a Mechanical Vapour Recompression (MVR) system for treating industrial effluent and 
installed Sewage Treatment Plants (STP) for domestic effluent management.
	
•	
Zero Liquid Discharge Policy: As part of its commitment to environmental sustainability, APL has implemented a 
zero liquid discharge policy across all its units. This policy ensures that no liquid waste is discharged, as all water 
resources are effectively treated and reused within its operations.
11.	 If the entity has operations/offices in/around ecologically sensitive areas (such as national parks, wildlife sanctuaries, 
biosphere reserves, wetlands, biodiversity hotspots, forests, coastal regulation zones etc.) where environmental 
approvals / clearances are required, please specify details.
	
None of our operational sites are situated in ecologically sensitive areas.
12.	 Details of environmental impact assessments of projects undertaken by the entity based on applicable laws, in the 
current financial year
	
No, during the reporting year there were no projects eligible for undertaking the EIA.
13.	 Is the entity compliant with the applicable environmental law/ regulations/ guidelines in India, such as the Water 
(Prevention and Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, Environment Protection Act and 
Rules thereunder (Y/N). If not, provide details of all such non-compliances.
	
Yes, Aarti Pharmalabs Limited is in full compliance with all applicable laws and regulations as per the Environmental 
Protection Act of 1986, the Water (Prevention and Control of Pollution) Act of 1974, and the Air (Prevention and Control of 
Pollution) Act of 1981. The company closely monitors and ensures adherence to these stringent environmental standards.
PRINCIPLE 7: BUSINESSES, WHEN ENGAGING   IN INFLUENCING PUBLIC AND REGULATORY POLICY, SHOULD DO SO IN A 
MANNER THAT IS RESPONSIBLE AND TRANSPARENT
Essential Indicators
1.	
 a.	
Number of affiliations with trade and industry chambers/ associations.
	
	
Currently, Aarti Pharmalabs is not affiliated with any chambers/associations, however the company is a participant 
of the United Nations Global Compact of India Network (UNGCI).
	
b.	
List the top 10 trade and industry chambers/ associations (determined based on the total members of such body) 
the entity is a member of/affiliated to:
	
	
Currently, Aarti Pharmalabs is not affiliated with any chambers/associations, however the company is a participant 
of the United Nations Global Compact of India Network (UNGCI).
2.	
Provide details of corrective action taken or underway on any issues related to anti- competitive conduct by the entity, 
based on adverse orders from regulatory authorities.
	
Nil. No adverse orders received from regulatory authorities.
PRINCIPLE 8: BUSINESSES, WHEN ENGAGING IN INFLUENCING PUBLIC AND REGULATORY POLICY, SHOULD DO SO IN A 
MANNER THAT IS RESPONSIBLE AND TRANSPARENT
Essential Indicators
1.	
Details of Social Impact Assessments (SIA) of projects undertaken by the entity based on applicable laws, in the current 
financial year
	
Not Applicable, the Company has not undertaken any SIA during the reporting period.
2.	
Provide information on project(s) for which ongoing Rehabilitation and Resettlement (R&R) is being undertaken by your 
entity
	
Not Applicable, the company has not undertaken any projects which required R&R.
Annual Report 2023-24
Corporate Overview
Statutory Reports
Financial Statements
113
1-31
32-115
116-256
3.	
Describe the mechanisms to receive and redress grievances of the community.
	
APL is deeply committed to being a responsible corporate citizen and maintaining positive relationships with the 
communities in which it operates. To enhance transparency and accountability, the company will establish a grievance 
redressal mechanism for these communities. This platform will allow community members to voice their concerns, provide 
feedback, and seek resolution regarding any operational issues. APL recognizes the importance of actively engaging with 
and addressing community concerns, and this mechanism will be crucial in fostering open dialogue and building trust.
4.	
Percentage of input material (inputs to total inputs by value) sourced from suppliers:
FY 2023-24
FY 2022-23
Directly sourced from MSMEs/ small producers
14.95%
14%
Sourced directly from within the district and neighbouring districts
15.22%
81%
5.	
Job creation in smaller towns – Disclose wages paid to persons employed (including employees or workers employed on 
a permanent or non-permanent / on contract basis) in the following locations, as % of total wage cost
Location
FY 2023-24
FY 2022-23
Rural
0
0
Semi-Urban
38.16%
39.84%
Urban
26.17%
26.70%
Metropolitan
35.67%
33.46%
PRINCIPLE 9: BUSINESSES SHOULD ENGAGE WITH AND PROVIDE VALUE TO THEIR CONSUMERS IN A RESPONSIBLE 
MANNER
Essential Indicators
1.	
Describe the mechanisms in place to receive and respond to consumer complaints and feedback.
	
APL has developed a robust system to effectively address and resolve consumer complaints. The company’s dedicated 
marketing department serves as the primary point of contact for these complaints, promptly forwarding them to the Quality 
department based on their nature and specifics.
	
APL prioritizes resolving consumer complaints quickly and efficiently. Our skilled and experienced Quality team diligently 
investigates each complaint to determine the appropriate course of action, ensuring the highest standards of product 
quality are maintained.
	
Committed to meeting customer expectations, APL aims to continuously improve its products and services through our 
consumer complaint resolution mechanism, thereby strengthening our bond with valued customers.
2.	
Turnover of products and/ services as a percentage of turnover from all products/service that carry information about
As a percentage to total turnover
Environmental and social parameters relevant to the product
100%, The company provides safety data sheets that 
are shared with the customers for all its products 
wherever applicable and as required. Our products 
are not sold to retail customers as it is and therefore 
product information is not provided.
Safe and responsible usage
Recycling and/or safe disposal 
3.	
Number of consumer complaints in respect of the following:
Category
FY 2023-24
Remarks
FY 2022-23
Remarks
Received 
during the 
year
Pending 
resolution at 
end of year
Received 
during the 
year
Pending 
resolution at 
end of year
Data privacy
0
0
-
0
0
-
Advertising
0
0
-
0
0
-
Cyber-security
0
0
-
0
0
-
Aarti Pharmalabs Limited
114
Category
FY 2023-24
Remarks
FY 2022-23
Remarks
Received 
during the 
year
Pending 
resolution at 
end of year
Received 
during the 
year
Pending 
resolution at 
end of year
Delivery of essential 
services
0
0
-
0
0
-
Restrictive Trade 
Practices
0
0
-
0
0
-
Unfair Trade 
Practices
2
1
APL shall ensure 
timely resolution 
of all the pending 
complaints
2
0
NA
Others
15
1
APL shall ensure 
timely resolution 
of all the pending 
complaints
16
3
All pending 
complaints have 
been closed.
4.	
Details of instances of product recalls on account of safety issues
Number
Reasons for recall
Voluntary recalls
0
NA
Forced recalls
0
NA
5.	
Does the entity have a framework/ policy on cyber security and risks related to data privacy? (Yes/No) If available, 
provide a web-link of the policy. 
	
Yes, APL has established rigorous measures and guidelines to protect sensitive information and maintain data confidentiality. 
The company adheres to an Information Security policy approved by the Board, demonstrating our dedication to data 
privacy and outlining specific measures implemented. For more details, please refer to the policy via the following web 
link: https://www.aartipharmalabs.com/investors/information-security-policy.pdf 
6.	
Provide details of any corrective actions taken or underway on issues relating to advertising, and delivery of essential 
services; cyber security and data privacy of customers; re-occurrence of instances of product recalls; penalty / action 
taken by regulatory authorities on safety of products / services. 
	
No incidents reported hence no corrective actions 
7.	
Provide the following information relating to data breaches:
	
a.	
Number of instances of data breaches - Nil
	
b.	
Percentage of data breaches involving personally identifiable information of customers - Nil
	
c.	
Impact, if any, of the data breaches – Not Applicable
Annual Report 2023-24
Corporate Overview
Statutory Reports
Financial Statements
115
1-31
32-115
116-256
